Skip to content
Company Analysis

Takeda Pharmaceutical Company L TAK

A comprehensive view of key metrics, scores, and financial health for Takeda Pharmaceutical Company L

Overview of Takeda Pharmaceutical Company Limited

TAK NYQ
Healthcare Drug Manufacturers - Specialty & Generic Framework: Pharma / Mature Biotech Large Cap
Takeda Pharmaceutical Company Limited (TAK), is a Large Cap company, in the Drug Manufacturers - Specialty & Generic industry, last closed at $15.91, about 18285.1% undervalued vs fair value, +4.7% 1Y return, placing in the top 10% of its sector.
Metrics P/E 0.4× Rev Growth 7.4% ROE 1.5% Gross Margin 65.5% Div Yield 641.66%
USD 15.91
0.25%
(Delayed)
• Vol 90d: 21.8%
52-Week Range
Market Cap
$49.54B
Enterprise Value
$4.25T
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Good
Health
Fair
Efficiency
Fair
Valuation
Fair
Growth
Fair
Profitability
Good
Health
Fair
Efficiency
Fair
Valuation
Fair
Completeness: 82%
Confidence: 55%
Updated: Mar 8
Top Beats

Quick Facts

Website https://www.takeda.com
HQ Tokyo
Employees 47,455
Fiscal year Mar 31

Next Events

Earnings Jul 30

Fair Value Snapshot

Bear Base Bull
$2649
$2925
$3218
Current: $15.91 +18285% vs base

Engine Room Money Flow™

Large Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$4.6T
7.5%%
Gross Profit
$3.0T
5.8%%
R&D Expense
$730.2B
0%%
Operating Income (EBIT)
$312.4B
81.3%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

Cash Conversion
338.4%
Excellent

Strong cash conversion - profit becomes cash

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$354.4B
52.3% of FCF

Where It Leaks

Cash Flow Health some concerns
Moderate efficiency issues detected. Review active leaks below for improvement areas.
4
Active Leaks
2/4
Improving
0
High Impact
0
Critical
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Takeda Pharmaceutical Company L's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
62
/100
Moderate
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Moderate
70
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 100% Coverage
Trade-Off Triangle Visualization A ternary plot showing TAK's balance between Growth (31.0%), Profitability (37.3%), and Safety (31.7%). Growth 31% Safety 32% Profitability 37%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

51th percentile vs peers
52
Key Signals
Rev Growth YoY 7.4% 55p Revenue CAGR 3Y 8.7% 58p TSR 5.65 98p EPS CAGR 3Y -22.8% 37p EPS Growth YoY -26.2% 25p
Strengths
  • TSR in top 20% of peers (5.65, 98th percentile)
  • Debt/FCF Ratio in top 20% of peers (6.66, 85th percentile)
  • Consistently strong margins across 5 metrics
  • Conservative leverage compared to industry peers
Risks

No significant risks identified for this axis.

Profitability

62th percentile vs peers
62
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

52th percentile vs peers
53
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Takeda Pharmaceutical Company L.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$2925.07
- - -
+18285.1% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000